A Cancer Drug Company Is Becoming Something Completely Different
Existing shareholders will end up with about 6.8% of what the merged company becomes. The cancer pipeline they backed does not survive the deal.
ticker-howl
1 storyCoverage
Existing shareholders will end up with about 6.8% of what the merged company becomes. The cancer pipeline they backed does not survive the deal.
One email each trading morning. Free.